Shares of Zymeworks Inc. (ZYME) plunged 6.91% on November 1, 2024, after the biopharmaceutical company received a downgrade from Wells Fargo and reported mixed results for its latest quarterly earnings.
Wells Fargo analysts downgraded their rating on Zymeworks from Overweight to Equalweight, setting a new price target of $12 per share, down from their previous target. The downgrade came as a surprise to investors and contributed to the significant selloff in ZYME stock.
Additionally, Zymeworks reported its earnings for the quarter ended January 1, 2024. While the company's revenue of $16 million slightly exceeded analyst expectations of $15.3 million, it reported an adjusted loss per share of $0.39, higher than the expected loss of $0.40 per share. The mixed results further weighed on investor sentiment, compounding the negative impact of the Wells Fargo downgrade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.